Eli Lilly and Co. recently submitted a supplemental new drug application to the U.S. Food and Drug Administration requesting that Cymbalta (duloxetine) be approved for the management of fibromyalgia. Cymbalta belongs to a class of drugs known as SNRIs (serotonin and norepinephrine reuptake inhibitors) and is currently approved for adults for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, and generalized anxiety disorder.
In the most recent of five clinical trials, Cymbalta was tested on fibromyalgia patients both with and without depression. The study results suggest that FM patients treated with 60mg or 120mg of Cymbalta experienced greater reduction in pain severity beginning one week after starting the drug than those receiving the placebo. At three and six months, patients showed a significantly greater reduction in pain and improvement in how they felt overall.
The most common side effects reported during the study were: nausea, dry mouth, constipation, sleepiness, fatigue, insomnia, decreased appetite, excessive perspiration, cough, tremor, rash and weight gain. Learn more about Cymbalta.
Published On: September 01, 2007